Rapid Plasma Membrane Anchoring of Newly Synthesized p59  fyn: Selective Requirement for NH2-Terminal Myristoylation and Palmitoylation at Cysteine-3 by Hof, Wouter van 't & Resh, Marilyn D.
 
ã
 
 The Rockefeller University Press, 0021-9525/97/03/1023/13 $2.00
The Journal of Cell Biology, Volume 136, Number 5, March 10, 1997 1023–1035 1023
 
Rapid Plasma Membrane Anchoring of Newly Synthesized p59
 
fyn
 
:
 
Selective Requirement for NH
 
2
 
-Terminal Myristoylation and
Palmitoylation at Cysteine-3
 
Wouter van ’t Hof and Marilyn D. Resh
 
Cell Biology and Genetics Program, Sloan-Kettering Institute for Cancer Research, New York, 10021
 
Abstract. 
 
The trafficking of Src family proteins after 
biosynthesis is poorly defined. Here we studied the role 
of dual fatty acylation with myristate and palmitate in 
 
biosynthetic transport of p59
 
fyn
 
. Metabolic labeling of 
 
transfected COS or NIH 3T3 cells with [
 
35
 
S]methionine 
followed by analysis of cytosolic and total membrane 
fractions showed that Fyn became membrane bound 
within 5 min after biosynthesis. Newly synthesized Src, 
however, accumulated in the membranes between 20–
60 min. Northern blotting detected Fyn mRNA specifi-
cally in soluble polyribosomes and soluble Fyn protein 
was only detected shortly (1–2 min) after radiolabeling. 
Use of chimeric Fyn and Src constructs showed that 
rapid membrane targeting was mediated by the myris-
toylated NH
 
2
 
-terminal sequence of Fyn and that a cys-
teine at position 3, but not 6, was essential. Examina-
tion of G
 
a
 
o
 
-, G
 
a
 
s
 
-, or GAP43-Fyn fusion constructs 
indicated that rapid membrane anchoring is exclusively 
conferred by the combination of N-myristoylation plus 
palmitoylation of cysteine-3. Density gradient analysis 
colocalized newly synthesized Fyn with plasma mem-
branes. Interestingly, a 10–20-min lag phase was ob-
served between plasma membrane binding and the 
acquisition of non-ionic detergent insolubility. We pro-
pose a model in which synthesis and myristoylation of 
Fyn occurs on soluble ribosomes, followed by rapid 
palmitoylation and plasma membrane anchoring, and a 
slower partitioning into detergent-insoluble membrane 
subdomains. These results serve to define a novel traf-
ficking pathway for Src family proteins that are regu-
lated by dual fatty acylation.
 
I
 
n
 
 fundamental cell biological processes such as signal
transduction at the plasma membrane or intracellular
membrane fusions during vesicular transport, cyto-
plasmic proteins are recruited to and released from the cy-
toplasmic surface of cellular membranes (6, 44). In order
to perform their functions at the correct time and place,
these cytoplasmic proteins must rely on regulated pro-
cesses guiding their binding to the cytoplasmic leaflet of
the membrane lipid bilayer (6, 19, 40, 41). In recent years,
modification with lipophilic moieties has been described
as an important mechanism involved in membrane an-
choring of cytoplasmic proteins. Two main types of pro-
tein acylation have been observed in eukaryotic cells: fatty
acylation with myristate and palmitate and isoprenoylation
with farnesyl or geranylgeranyl moieties (6, 19, 20, 40, 56).
Many acylated proteins contain a combination of two
membrane anchoring features (40, 41). This “two-signal
mode” for membrane anchoring (40, 41) is highlighted by
proteins belonging to the Src family and 
 
a
 
 subunits of het-
erotrimeric G–protein complexes, which are modified at
their NH
 
2
 
-termini with both myristate and palmitate (40).
Proteins belonging to the Ras and Rab families carry the
combination of isoprenyl groups and palmitate at their
COOH-termini (16, 41). In addition, for Src, HIV-Gag-1
and the MARCKS protein, N-myristoylation has been ob-
served in combination with NH
 
2
 
-terminal clusters of basic
amino acids (32, 49, 50, 57). These basic motifs have been
reported to direct membrane association by interaction
with negatively charged phospholipids enriched in the cy-
toplasmic leaflet of cellular membranes (reviewed in [39]).
Interestingly, a similar combination, consisting of farnesy-
lation plus a basic amino acid motif, has been observed at
the COOH terminus of the K-Ras4B isoform (31), show-
ing that the two signal combinations are conserved and
can act at either the NH
 
2
 
- and the COOH-termini of pro-
teins (40, 41).
Members of the Src family of nonreceptor tyrosine ki-
nases all share extensive sequence homology with the
proto-oncogene pp60
 
src
 
. The nine members Src, Yes, Lck,
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Fyn, Lyn, Yrk, Blk, Hck, and Fgr contain four regions of
sequence similarity, called Src Homology (SH)
 
1
 
 domains.
These include the COOH-terminal tyrosine kinase (SH1)
and the internal SH2 and SH3 domains. The fourth con-
sensus sequence, SH4, is located on the NH
 
2
 
 terminus and
carries the signals involved in the attachment of the fatty
acids myristate and palmitate (40). The covalent attach-
ment of myristate to an NH
 
2
 
-terminal glycine occurs co-
translationally (54) and is mediated by the soluble enzyme
N-myristoyl transferase (NMT) (20, 51). Recently, it was
shown that several Src family members are also modified
with palmitate (1, 34, 48) and that dual fatty acylation with
myristate and palmitate regulates their membrane binding
and subcellular distribution (1, 42, 43).
Currently, the molecular mechanism for trafficking of
dually acylated Src family proteins from their site of syn-
thesis to the membrane, remains poorly defined. Using
p59
 
fyn
 
 (1) as a model, we have studied the role of N-myris-
toylation plus palmitoylation in the trafficking Src family
proteins after biosynthesis. We observed that newly syn-
thesized Fyn became rapidly bound to the plasma mem-
brane, within 5 min after biosynthesis, whereas newly syn-
thesized v-Src required 20–60 min to accumulate in the
membrane fraction. Northern blotting confirmed that Fyn
is initially synthesized on soluble ribosomes in the cyto-
plasm. Experiments with mutant or chimeric Fyn con-
structs indicated that the rapid membrane targeting of bio-
synthetic Fyn is directed by its NH
 
2
 
-terminal sequence.
Subsequent mutational analysis showed that the rapid
membrane binding phenotype of newly synthesized Fyn is
encoded exclusively by the combination of N-myristoyla-
tion and palmitoylation at cysteine-3. In labeling experi-
ments that were combined with extraction with the non-
ionic detergent Triton X-100, a significant lag-phase was
observed between membrane binding and the acquisition
of complete detergent insolubility of biosynthetic Fyn, in-
dicating that dual acylation of Fyn is not a direct targeting
signal for association with detergent resistant plasma
membrane complexes. We present a model for the biosyn-
thetic pathway for Fyn, in which cotranslational N-myris-
toylation on soluble ribosomes is rapidly followed by
palmitoylation at cysteine-3 and plasma membrane an-
choring, followed by association of Fyn with the detergent
resistant matrix.
 
Materials and Methods
 
Materials
 
Cell culture reagents and RNA molecular weight markers were purchased
from Gibco Laboratories (Grand Island, NY). cDNAs for human Fyn, c-Src,
or v-Src in pCMV-5 (1) and p65-VALO (37), containing full-length 
 
b
 
-galac-
tosidase from 
 
E. coli
 
 were used from lab stocks. Human TGF-
 
b
 
 I Recep-
tor cDNA (14), modified with an HA tag and subcloned into pCMV-5
(53) and rabbit polyclonal antiserum against human TGF-
 
b
 
 I Receptor were
kindly provided by Drs. Joan Massagué and Frances Weis-Garcia (Sloan-
Kettering Institute, New York). [
 
35
 
S]Methionine (Tran
 
35
 
S-label), 9,10-
[
 
3
 
H]myristate, 9,10-[
 
3
 
H]palmitate, [
 
125
 
I]Na-I and [
 
a
 
-
 
32
 
P]dCTP were pur-
 
chased from DuPont New England Nuclear (Boston, MA). Synthesis and
radioiodination of IC-16 and IC-13 fatty acid analogues were performed
as previously described (4). Rabbit polyclonal antisera raised against Fyn
SH43 protein, containing amino acids 1-148 of Fyn (4), or v-Src were from
lab stocks. Rabbit anti–
 
b
 
-galactosidase polyclonal antiserum was from
Promega (Madison, WI) and protein A–agarose was from Santa Cruz (Palo
Alto, CA). 4-Methylumbelliferone substrates were from Sigma Chem. Co.
(St. Louis. MO) and OptiPrep
 
TM
 
 was purchased from Nycomed Pharma
(Oslo, Norway).
 
Construction of Fyn Chimeras (G
 
a
 
o
 
(10)-Fyn,
G
 
a
 
s
 
(10)-Fyn, and GAP43(10)-Fyn
 
Chimeric cDNAs in which the first 10 amino acids of Fyn were replaced
by the corresponding sequences of G
 
a
 
o
 
, G
 
a
 
s
 
 (23), or GAP43 (22) were
generated by PCR using the following procedure. Sense oligonucleotides
were synthesized to encode the upstream region of pGEM3Z, followed by
the first 10 amino acids of human G
 
a
 
o
 
 or G
 
a
 
s
 
 and amino acids 11-15 of hu-
man Fyn. For the GAP43 construct a sense oligonucleotide was synthe-
sized to encode a BamHI site, the upstream region of pGEM3Z, the first
10 amino acids of human GAP43 and amino acids 11-15 of human Fyn.
An antisense oligonucleotide was used corresponding to a region of the
SH3 domain of Fyn (1). These primers were used with pGEM3Z-Fyn as a
template to generate chimeric cDNAs by PCR. The PCR products ob-
tained using the G
 
a
 
o
 
 or G
 
a
 
s
 
 sense primers were digested with NcoI and
BstXI to generate 76 basepair fragments that were used to replace the cor-
responding fragments of Fyn in pSP65. The PCR product obtained using
the GAP43 sense primer was digested with BamHI and BstXI to generate
a 100-bp fragment that was used to replace the corresponding fragment of
Fyn in pSP65. The constructs were subsequently digested with EcoRI and
SalI, followed by ligation of G
 
a
 
o
 
(10)-Fyn, G
 
a
 
s
 
(10)-Fyn, or GAP43(10)-
Fyn chimeric cDNA into EcoRI and SalI cut pCMV5. All constructs were
verified by DNA sequencing before use in transfection studies.
 
Cell Culture, Transfection, and Metabolic Labeling
 
COS-1 cells (ATCC) were grown in DMEM, supplemented with 10% FBS
(Gemini Bioproducts), penicillin (50 U/ml), and streptomycin (50 
 
m
 
g/ml).
Stable clones of NIH-3T3 cells expressing human wt Fyn were grown in
DMEM, supplemented with 10% calf serum, penicillin (50 U/ml), and
streptomycin (50 
 
m
 
g/ml). Cells were cultured in an atmosphere of 5% CO
 
2
 
at 37
 
8
 
C and were passaged every 2–3 d. COS-1 cells were transfected ac-
cording to the DEAE-dextran method as follows. Semi-confluent mono-
layers on 100-mm plastic tissue culture dishes were incubated for 2.5 h at
37
 
8
 
C with DMEM containing 10% Nu Serum (Collaborative Research
Labs, Bedford, MA), 100 
 
m
 
M chloroquine, 400 
 
m
 
g/ml DEAE-dextran, and
5–10 
 
m
 
g DNA. Cells were incubated for 1 min in PBS containing 10%
DMSO, washed with DMEM, and incubated overnight in DMEM con-
taining 10% FBS. The next day, cells were trypsinized and experiments
were performed the following day (2 d after transfection). Transfected
cells were metabolically radiolabeled at 37
 
8
 
C with 100 or 500 
 
m
 
Ci/ml
[
 
35
 
S]methionine, after starvation for 1 h at 37
 
8
 
C in DMEM minus me-
thionine, containing 2% dialyzed FBS. For radiolabeling with fatty acids,
cells were starved for 1 h at 37
 
8
 
C in DMEM containing 2% dialyzed FBS,
followed by incubation with either 20 
 
m
 
Ci/ml [
 
3
 
H]myristate or 100 
 
m
 
Ci/ml
[
 
3
 
H]palmitate at 37
 
8
 
C. Alternatively, 10–20 
 
m
 
Ci/ml [
 
125
 
I]IC-13 or [
 
125
 
I]IC-
16 were used (1, 36). Labeling experiments up to 20 min were performed
in a waterbath at 37
 
8
 
C in media supplemented with 50 mM Hepes, pH 7.4.
Radiolabeling for longer times was performed in a tissue culture incubator
with pre-equilibrated medium.
 
Extraction of Transfected Cells with
Non-ionic Detergent
 
Radiolabeled COS-1 or NIH-3T3 cells were extracted with a 1% Triton
X-100 solution as previously described (17). Cells on 60-mm dishes were
rinsed with ice-cold STE (50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA) and incubated for 5 min at 4
 
8
 
C with 0.8-ml Csk buffer (10 mM
Pipes pH 6.8, 100 mM KCl, 2.5 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 300 mM sucrose,
and 1% Triton X-100) containing protease inhibitors (1 mM PMSF, 10 
 
m
 
g/ml
leupeptin, and 10 
 
m
 
g/ml aprotinin), followed by 0.2 ml fresh buffer for 1 min.
The two detergent washes, containing detergent soluble (S) material, were
pooled and 0.25 ml 5
 
3
 
 lysis buffer was added. The remaining fraction on the
dishes, containing detergent resistant (R) material, was subsequently
scraped from the plate in 1 ml 1
 
3
 
 lysis buffer (50 mM Tris, pH 8.0, 150 mM
 
1. 
 
Abbreviations used in this paper
 
: IC-13, 13-[
 
125
 
I] iodotridecanoic acid;
IC-16, 16-[
 
125
 
I] iodohexadecanoic acid; NMT, N-myristoyl acyltransferase;
PAT, palmitoyl acyltransferase; SH, Src Homology domain; TBR-I, trans-
forming growth factor 
 
b
 
 type-I receptor. 
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NaCl, 2 mM EDTA, 1% NP-40, 0.5% deoxycholate, 5 mM NaF). Both
fractions were clarified for 15 min at 100,000 
 
g
 
 and analyzed by immuno-
precipitation and SDS-PAGE as described below.
 
Subcellular Fractionation and Marker Enzyme Analysis
 
Analysis of Cytosol (S100) and Total Membranes (P100).  
 
Radiolabeled cells
were washed and scraped from the dishes in ice-cold STE. Cells were spun
for 5 min at 1,500 rpm in a refrigerated tabletop centrifuge, resuspended
in hypotonic buffer (10 mM Tris/HCl pH 7.2, 0.2 mM MgCl
 
2
 
, 100 mM
Na
 
3
 
VO
 
4
 
) supplemented with protease inhibitors, and incubated on ice for
10 min, followed by homogenization with 25 strokes in a 1.5-ml Dounce
homogenizer with a tight pestle. The homogenate was adjusted to 250 mM
sucrose and 1 mM EDTA and centrifuged for 45 min at 100,000 
 
g
 
 (50,000
rpm in TLA 100.2 or 100.3 rotor) in an Optima TL Ultracentrifuge (Beck-
man Instrs., Fullerton, CA). The pellet (P100), containing total cellular
membranes, was resuspended in lysis buffer supplemented with protease
inhibitors and the soluble fraction (S100) was supplemented with 0.2 vol
of 5
 
3
 
 concentrated lysis buffer. Samples were lysed for 15 min on ice, clar-
ified by centrifugation for 15 min at 100,000 
 
g
 
 and immunoprecipitated.
Antibody titration experiments were performed to verify that immuno-
precipitation reactions occurred under conditions of antibody excess,
allowing for quantitative recovery of Fyn and Src from P100 and S100
fractions.
 
Analysis of Linear Density Gradients.  
 
The following modifications were
made for analysis of the intracellular distribution of biosynthetic Fyn.
Only stably transfected NIH-3T3 cells were used for linear density gradi-
ent analysis. All steps were performed with an isotonic homogenization
buffer (0.25 M Sucrose, 20 mM Hepes, pH 7.4, 1 mM EDTA), containing
protease inhibitors. For each individual gradient, cells from six sub-conflu-
ent 100-mm plastic dishes were used equivalent to roughly 10 mg cellular
protein. Cells were scraped, spun down for 5 min at 1,500 rpm, resus-
pended in 1 ml isotonic homogenization buffer with protease inhibitors,
and homogenized with 15 strokes in a 1.5-ml Dounce homogenizer with a
tight pestle. Nuclei and unbroken cells were removed by centrifugation
for 10 min at 500 
 
g.
 
 The Dounce homogenizer was rinsed with 0.2 ml ho-
mogenization buffer and this solution was used to resuspend the nuclear
pellet, followed by a respin for 10 min at 500 
 
g.
 
 Subsequently, the com-
bined postnuclear supernatants (PNS) were centrifuged for 45 min at
100,000 
 
g
 
, and the resulting P100 fraction was resuspended in 1 ml isotonic
homogenization buffer with protease inhibitors by five strokes in the
Dounce homogenizer and layered on top of continuous iodixanol density
gradients (25.0–2.5% wt/vol OptiPrep
 
TM
 
, from stock solution diluted in
0.25 M sucrose/TE). Gradients were centrifuged for 3 h at 100,000 
 
g
 
 (38K
in SW40Ti rotor) and fractionated into 
 
z
 
0.7 ml samples, starting from the
bottom of the gradient. For analysis of marker enzyme activities, 20–50-
 
m
 
l
samples were taken from each fraction. Assays, routinely performed in
duplicates in 96-well microtiter plates (Costar, Boston, MA), were started
by adding 200 
 
m
 
l enzyme assay mixed to each sample. 
 
a
 
-Glucosidase II ac-
tivity was assayed in 150 mM Citrate/phosphate pH 6.5, 1 mM 4-Meth-
ylumbelliferone-
 
a
 
-
 
d
 
-glucoside, 
 
a
 
-Mannosidase II in 150 mM phosphate
buffer, pH 6.0, containing 0.02% Triton X-100, 1 mM 4-Methylumbellifer-
one-
 
a
 
-
 
d
 
-mannopyranoside, and alkaline phosphatase activity was mea-
sured in 100 mM Tris/NaOH pH 9.5, 100 mM NaCl, 5 mM MgCl
 
2
 
, 1 mM
4-Methylumbelliferone-phosphate. Reactions were allowed to proceed for
2–4 h at 37
 
8
 
C and stopped by addition of 100 
 
m
 
l ice-cold 1 M Glycine/
NaOH, pH 10, 1 M Na
 
2
 
CO
 
3
 
. Fluorescence was measured at 
 
l
 
ex
 
 360 nm,
 
l
 
em
 
 460 nm using a CytoFluor
 
TM
 
 2350 Fluorescence measurement system
(Millipore, Bedford, MA).
 
Immunoprecipitation, Gel Electrophoresis,
and Quantitation
 
To each clarified sample in lysis buffer either 2 
 
m
 
l anti-Fyn, 2 
 
m
 
l anti-Src, 1 
 
m
 
l
anti-TBR I, or 1 
 
m
 
l anti-
 
b
 
-Gal rabbit polyclonal antiserum was added. Af-
ter addition of 10 
 
m
 
l protein A–agarose solution, samples were incubated
for 2–12 h at 4
 
8
 
C. Immunoprecipitates were washed twice with lysis buffer
and once with TE (10 mM Tris/HCl, pH 7.2, 1 mM EDTA) and analyzed by
SDS-PAGE. Radiolabeled proteins were visualized by exposure to X-omat
or BioMax film (Eastman Kodak, Rochester, NY) and quantified by cut-
ting out gel slices, followed by liquid scintillation counting in EcoLume
(ICN, Costa Mesa, CA). Alternatively, gels were exposed to phosphorim-
ager screens and quantitation was performed using the ImageQuant soft-
ware provided with the phosphorimager system (Molecular Dynamics,
Sunnyvale, CA).
 
Analysis of Soluble and
Membrane-bound Polyribosomes
 
All steps were performed at 4
 
8
 
C under RNAse-free conditions and all so-
lutions, buffered with Hepes instead of Tris, were pretreated with 0.2%
DEPC and supplemented with 5 mM DTT and 0.5 U/ml rRNAsin (New
England Biolabs, Beverly, MA).
 
Flotation Assay for Membrane-bound Polysomes.  
 
The protocol was adapted
from the nascent chain targeting assay by Lauring et al. (24). Homoge-
nization of transfected cells was performed with hypotonic buffer, con-
taining 10 mM Hepes/KOH, pH 7.4. Postnuclear supernatants were ad-
justed to 50 mM Hepes/KOH, pH 7.4, 50 mM KOAc, and 5 mM
Mg(OAc)
 
2
 
 (HKM buffer), layered on top of a 2-ml cushion of 1 M su-
crose/HKM, and centrifuged for 2 h at 200,000 
 
g
 
 in an SW 55Ti rotor
(46,000 rpm). The supernatant and sucrose cushion were discarded and
the polyribosomal pellet was carefully resuspended in 1 ml 2.1 M sucrose/
HKM. Subsequently, a discontinuous sucrose gradient was generated by
overlayering with 3 ml of 1.9 M sucrose/HKM and 1 ml HKM, respec-
tively. After a centrifugation step for 2 h, at 200,000 
 
g
 
, membrane-bound
(Mb) ribosomes were collected from the 1.9-M sucrose, HKM interface,
whereas soluble (S) polysomes were collected from the 2.1 M sucrose
cushion. Membrane and soluble polysomal samples were diluted in 5 vol
of HKM, and polyribosomes were precipitated by centrifugation for 2 h at
200,000 
 
g.
 
RNA Extraction and Northern Blotting Analysis.  
 
Membrane-bound and
soluble polyribosomes were resuspended in 1 ml Ultraspec RNA solution
(Biotecx, Houston, TX) and incubated for 10 min at 4
 
8
 
C. After addition of
200 
 
m
 
l chloroform and centrifugation for 10 min in an Eppendorf centri-
fuge, the clear upper-phases containing the RNA were collected, supple-
mented with equal volumes of 2-propanol, and incubated for 10 min at
48C. After centrifugation for 15 min at top speed in an Eppendorf centri-
fuge, RNA pellets were washed with 80% ethanol in TE, air-dried for 2–3
min under vacuum and redissolved in 10 ml TE. Routinely, 1 ml was tested
for rRNA intactness on a 1% agarose gel and the remainder was resolved
on a 1% formaldehyde-agarose gel, followed by transfer to GeneScreen
Plus hybridization transfer membranes (DuPont NEN) and UV-cross-
linking of RNA to the membranes using a Stratalinker (Stratagene, La
Jolla, CA). Fyn, v-Src, or TBR-I RNA species on hybridization mem-
branes were detected with random-primed (Stratagene) 32P-labeled frag-
ments that were synthesized using the following DNA templates. A specific
template for Fyn, an 0.7-kB cDNA fragment encoding the NH2-terminal
Fyn sequence, was obtained by gel purification after SmaI digestion of
pSP65-Fyn (1). For v-src, a 1.9-kB fragment encoding the entire gene, was
obtained after NcoI and BglII digestion of pGEM3z-v-src (1). An 0.8-kB
template for TBR-I, encoding its unique NH2-terminal ectodomain (14),
was prepared by HindIII and XbaI digestion of pCMV5-TBR I-HA, fol-
lowed by gel purification. Blots were first incubated for 1 h at 428C with
hybridization solution (53 SSPE, 53 Denhardt solution, 50% formamide,
1% SDS, 10% dextran sulphate, and 100 mg/ml denatured salmon sperm
DNA), then overnight at 428C with 0.5 3 106 cpm/ml denatured random
probes in fresh hybridization buffer without salmon sperm DNA. The
blots were washed twice for 15 min at RT with 1.03 SSPE/0.1% SDS and
once with 0.23 SSPE/0.1% SDS for 15 min at 508C before exposure to X-ray
film or phosphorimager screens. For reprobing, blots were stripped by
washing twice for 30 min at 808C in 0.053 SSPE, 0.01 M EDTA, and 0.1%
SDS, rinsed with 0.013 SSPE for 15 min at RT and hybridized as before.
Results
Newly Synthesized Fyn Is Rapidly Directed to 
Membrane Fractions
The subcellular distribution of newly synthesized Fyn and
Src was studied by fractionation of pulse radiolabeled cells
into cytosolic (S100) and total membrane (P100) fractions.
COS-1 cells, transfected with wt Fyn or v-Src were radiola-
beled for 5, 10 or 20 min at 378C with [35S]methionine, fol-
lowed by homogenization and centrifugation at 100,000 g.
Analysis of S100 and P100 fractions by immunoprecipita-
tion (Fig. 1) revealed that newly synthesized Fyn was pre-
dominantly (.85%) in the membrane fractions after 5, 10
and 20 min of radiolabeling (Fig. 2 A). At these time-The Journal of Cell Biology, Volume 136, 1997 1026
points, significant amounts (z55%) of newly synthesized
v-Src were still observed in the soluble fractions, followed
by accumulation in the membrane fraction after radiola-
beling for 120 min (Fig. 2 B). Identical results were ob-
tained using constructs encoding c-Src instead of v-Src in
COS-1 cells (not shown). As controls, COS-1 cells were
transfected with transforming growth factor b type-I re-
ceptor (TBR-I), a transmembrane protein, and b-Galac-
tosidase (b-Gal), a soluble protein. TBR-I was consis-
tently present in the P100 fractions (Figs. 1 and 2 C), and
b-Gal was primarily recovered from the S100 fractions
(Figs. 1 and 2 D), confirming the identity of the cytosolic
and total membrane fractions.
Control experiments were performed to verify that ac-
cumulation of biosynthetic Fyn and Src in the P100 frac-
tions was caused by binding to membranes, rather than
aggregation of overexpressed protein into insoluble com-
plexes. P100 fractions from cells radiolabeled with [35S]methi-
onine for 5 min were resuspended, layered on 50% (wt/wt)
sucrose cushions, and centrifuged for 1 h at 100,000 g. Dur-
ing centrifugation, membrane-bound material accumulates
on top of the high density sucrose solutions, due to the
buoyant density of membrane lipids, whereas insoluble
material migrates through the sucrose cushion and pellets
on the bottom of the tube. After centrifugation, samples
were collected from the top of the 50% sucrose cushion
and the pellet, and analyzed by immunoprecipitation. In
two experiments, 86 6 4% of radiolabeled Fyn and 96 6
4% Src was recovered from the top of the 50% sucrose
cushion, confirming the membrane-bound nature of newly
synthesized Fyn and Src in the P100 fractions (Figs. 1 and 2).
Fyn Is Synthesized on Free Polyribosomes
in the Cytoplasm
Most membrane proteins are synthesized on membrane-
bound ribosomes, by virtue of an NH2-terminal signal se-
quence that directs cotranslational anchoring to the ER
membrane (52). Although Fyn has no apparent NH2-termi-
nal signal sequence for cotranslational membrane anchor-
ing, the membrane binding behavior of the newly synthe-
sized Fyn polypeptide is similar to that of transmembrane
proteins (cf. Fig. 2, A and C). To determine the site of syn-
thesis of Fyn protein, the localization of Fyn mRNA was
assessed. The distribution of Fyn mRNA was compared to
that of v-Src specific mRNA, which is known to be local-
ized to free polyribosomes (25) and the mRNA specific for
the type I transmembrane protein TBR-I (14), made on
membrane-bound polysomes. COS-1 cells were cotrans-
fected with cDNAs for Fyn, v-Src, and TBR-I, polyribo-
somes were isolated and fractionated into free and mem-
brane-bound fractions (24), followed by mRNA isolation
and separation on agarose/formaldehyde gels. After trans-
fer to hybridization membranes, RNA species specific for
Fyn, v-Src, and TBR-I were visualized and measured, using
specific 32P-labeled probes. For Fyn, a single RNA species
of z2.2 kB (Fig. 3 A) was found to be enriched in the solu-
ble polyribosomal fraction (Fig. 3, A and B). The Fyn
mRNA was of appropriate size (2) and its distribution was
identical to that of v-Src mRNA, observed as a single spe-
Figure 1. Subcellular distribution of newly synthesized Fyn and
marker proteins in COS-1 cells. COS-1 cells were transfected
with cDNAs encoding wild-type Fyn, v-Src, TBR-I, or b-galac-
tosidase as described under Materials and Methods. Transfected
cells on 60-mm plastic dishes were radiolabeled with 100 mCi/ml
[35S]methionine for 5, 10, or 20 min at 378C, followed by homoge-
nization and fractionation into a cytosolic (S100) and a total cel-
lular membrane (P100) fraction, by centrifugation for 45 min at
100,000 g. The subcellular distribution of Fyn and marker pro-
teins between the soluble and membrane fractions was analyzed
by immunoprecipitation, followed by SDS-PAGE and autora-
diography. Gels were exposed to film for 8–16 h.
Figure 2. Quantitation of the subcellular distribution of newly
synthesized Fyn. Cells were transfected, radiolabeled for the indi-
cated amounts of time, homogenized and fractionated as de-
scribed in the legend to Fig. 1. After detection of proteins by
autoradiography, the radiolabeled bands were excised and quan-
tified by liquid-scintillation counting. Total cpm after 5, 10, 20,
and 120 min of labeling were Fyn (A) 642, 1699, 3542, and 28209
cpm, respectively; Src (B) 542, 1400, 2244, and 16223 cpm; TBR-I
(C), 964, 2481, 3397, and 10668; b-galactosidase (D), 318, 922,
1894, and 13569. These numbers for total label incorporation rep-
resent the mean of three independent experiments, with individ-
ual measurements ranging within 20% of the mean. Blanks, mea-
sured by excising gel-slices in control lanes, contained 71 6 3 cpm
(n 5 16).van ’t Hof and Resh Biosynthesis and Plasma Membrane Targeting of Fyn 1027
cies of z2.4 kB (Fig. 3, A and B). In contrast, the majority
of TBR-I specific mRNA (z3.0 kB; Fig. 3 A) was recov-
ered from the membrane fraction (Fig. 3 B). No significant
degradation for any of the mRNA species was observed
(Fig. 3 A). Taken together, these results establish that Fyn
is synthesized on soluble polyribosomes in the cytoplasm.
In the next experiment, the time scales of radiolabeling
with [35S]methionine were reduced in order to detect solu-
ble Fyn precursors (Fig. 4). A significant amount (45%) of
Fyn was detected in the S100 fraction after 1 min of radio-
labeling at 378C (Fig. 4 A). This soluble pool rapidly de-
creased to 35% and 25% after 2- and 4-min labeling, re-
Figure 3. Northern blotting analysis of Fyn mRNA in soluble and membrane-bound polyribosomes. COS-1 cells were cotransfected with
cDNAs for Fyn, Src, or TBR-I. Soluble and membrane-bound polyribosomal complexes were isolated as described under Materials and
Methods. The detection of specific mRNA species in free or membrane-bound polyribosomal samples was performed by Northern blot
analysis, using 32P-labeled fragments specific for Fyn, v-Src, or TBR-I. (A) Distribution of Fyn, Src, or TBR-I specific mRNA in soluble
(Sol) and membrane-bound ribosomes (Mb). From top to bottom, markers indicate the migration of RNA species of 7.5; 4.4; 2.4; 1.4;
and 0.2 kB, respectively. Blots were exposed to film for 2–5 d. (B) Quantitation of the relative distribution of Fyn, Src, and TBR-I
mRNA between soluble and membrane-bound ribosomes, measured by phosphorimager analysis. Values represent the mean of four in-
dependent experiments. Blots were exposed to phosphorimager screens for 12–36 h.
Figure 4. Subcellular distribution of newly synthesized Fyn, radiolabeled for 1, 2, and 4 min. COS-1 cells were transfected with Fyn or Src
cDNA, homogenized, and fractionated as described in the legend to Fig. 1. Transfected cells on 100-mm plastic dishes were radiolabeled
for 1, 2 or 4 min with 100 mCi/ml [35S]methionine at 378C and radiolabeled Fyn and Src were immunoprecipitated and applied to SDS-
PAGE, followed by autoradiography and quantitation by liquid-scintillation counting. In two experiments, total counts for Fyn (A)
were 456, 1035, and 2617 cpm, after 1, 2, and 4 min at 378C, respectively. For Src (B) numbers were 237, 1357, and 2888 cpm, respectively.
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spectively, concomitant with a corresponding increase of
radiolabeled Fyn in the P100 fractions (Fig. 4 A). In con-
trast, the distribution of v-Src after 1-, 2-, and 4-min label-
ing (Fig. 4 B) showed no significant changes compared to
longer labeling times (Fig. 2 B). These observations indi-
cate that immediately after biosynthesis (,1 min), Fyn ex-
ists as a soluble cytoplasmic protein, which subsequently
becomes membrane bound between 2–4 min. Experiments
to test for the accumulation of the soluble form of newly
synthesized Fyn at lower temperatures (258C, 208C, or
158C) or after energy (ATP) depletion, were unsuccessful
because levels of radiolabel incorporation were limiting
under these conditions (not shown).
Rapid Membrane Targeting of Newly Synthesized Fyn 
in Stably Transfected NIH-3T3 Cells
Since exogenous protein in transfected COS-1 cells can be
overexpressed 20–50-fold above endogenous levels, it is
possible that highly overexpressed protein may exhibit ab-
errant behavior. To test if the observed rapid membrane
targeting of Fyn in COS-1 cells is a general phenomenon
or an artifact driven by protein overexpression, we studied
Fyn and v-Src in stably transfected NIH-3T3 cells, in which
overexpression levels range from 5–10-fold. Confluent
monolayers of Fyn or Src expressing 3T3 cell lines were ra-
diolabeled with [35S]methionine at 378C and fractionated
into S100 and P100 fractions as before. The distribution of
Fyn and v-Src was analyzed by immunoprecipitation and
SDS-PAGE, followed by quantitation through phosphor-
imaging. Expression levels in NIH-3T3 cells were con-
firmed to be much lower than in COS-1, as indicated by
the longer exposure times to film and phosphorimager
screens (see legends to Figs. 1 and 5). Analysis from three
different experiments showed that in NIH-3T3 cells, newly
synthesized Fyn was also rapidly targeted to the mem-
brane fraction (Fig. 5). Initially, 1 min after biosynthesis,
50% of Fyn was soluble. Within 3 min, steady-state levels
of membrane binding (90% in P100) were observed (Fig.
5). In contrast, analysis of v-Src in 3T3 fibroblasts shows
that membrane-binding of v-Src was much slower (Fig. 5).
Binding was linear for up to 20 min, and the steady state
distribution (70% in P100) was only reached between 20
and 60 min. Interestingly, in experiments with 3T3 fibro-
blasts, the levels of Fyn in the S100 at steady state were
lower (5–9%, Fig. 5) than those in COS-1 cells (15–25%,
Fig. 2 A), indicating that overexpression of Fyn in COS-1
may lead to a slight buildup of Fyn in the cytosolic frac-
tion. The experiments with 3T3 fibroblasts again serve to
highlight the obvious difference between “rapid” mem-
brane targeting of Fyn and the “slow” membrane binding
of v-Src after biosynthesis.
Rapid Membrane Targeting of Fyn Depends on 
Myristoylation and a Cysteine at Position-3
Membrane binding of a variety of chimeric and mutant
Fyn and v-Src constructs (1) (summarized in Table I) was
monitored in order to unravel the mechanism behind the
rapid biosynthetic membrane anchoring of Fyn. We fo-
cused on the NH2-terminal SH4 region of Fyn which is
known to contain the signals for membrane anchoring (1).
Use of the Fyn(14)Src chimera, in which the first 14 amino
acids of Fyn replaced those of v-Src (1), showed that these
first 14 amino acids of Fyn were sufficient to induce rapid
membrane targeting of v-Src, as illustrated by rapid accu-
mulation of biosynthetic Fyn(14)Src in the P100 fractions
(Fig. 6 B). Conversely, replacement of the first 14 amino
acids of Fyn by the corresponding amino-terminal se-
quence of v-Src (Src(14)Fyn), resulted in slow membrane
Figure 5. Membrane binding of newly synthesized Fyn and v-Src
in stably transfected NIH-3T3 cells. NIH-3T3 cells stably express-
ing human Fyn or v-Src were radiolabeled for the indicated time
intervals with 100 mCi/ml [35S]methionine at 378C. Cells were
fractionated into S100 and P100 fractions as before and the distri-
bution of Fyn and v-Src was analyzed by immunoprecipitation
and SDS-PAGE, followed by quantitation by phosphorimaging
after exposure for 7–14 d. In this figure and in the following fig-
ures, values represent the amount recovered in P100 fractions, as
the percentage of total. These values are the mean of two or three
experiments, with individual measurements ranging within 10%
of the mean. Background values, measured in each individual
lane containing radiolabeled protein, represented 20 6 15% of
total signal for Fyn (n 5 12), and 10 6 8% for v-Src (n 5 8).
Table I. Amino-Terminal Sequences of wt and Mutant Fyn
and Src
Amino acid position
1234567891 0
Fyn Myr------- G C V Q C K D K E
G2A-Fyn A C V Q C K D K E
C3S-Fyn Myr------- G S V Q C K D K E
C6S-Fyn Myr------- G C V Q S K D K E
Src Myr------- G S S K S K P K D
S3C-Src Myr------- G C S K S K P K D
S6C-Src Myr------- G S S K C K P K D
Gao Myr------- G C T L S A E E R
Gas M G C L G N S K T E
GAP-43 ML  C C M R R T K Q
The sequences of the first ten amino acids of each Fyn construct are shown with mu-
tant amino acids underlined. Point mutants were constructed by site-directed mutagen-
esis (1). The G2A-Fyn mutant has glycine-2 replaced by alanine, resulting in loss of
myristoylation (1). C3-S-Fyn and C6S-Fyn, respectively, have cysteines at positions 3
and 6 replaced by serines. In the S3C-Src and S6C-Src mutants serines at positions 3
and 6, respectively, are replaced by cysteines. In the Gao(10)Fyn, Gas(10)Fyn, and
GAP43(10)Fyn chimeric constructs (see Materials and Methods), the first 10 amino
acids of Fyn have been replaced with the corresponding sequences of human Gao, Gas
(23), or GAP43 (22).van ’t Hof and Resh Biosynthesis and Plasma Membrane Targeting of Fyn 1029
anchoring of newly synthesized Fyn (Fig. 6 A), very similar
to v-Src (Figs. 1, 2, and 5). Myristoylation was a prerequi-
site for membrane anchoring, as evidenced by the consis-
tently lower amounts (z30%) of the nonmyristoylated
G2A-Fyn mutant in the membrane fractions (Fig. 6 A).
Next, a series of point mutations were used, containing
cysteine to serine replacements and vice versa, to elimi-
nate or introduce palmitoylation sites (1). Analysis of C3S-
Fyn and C6S-Fyn mutants (Table I) showed that rapid
membrane targeting of newly synthesized Fyn was selec-
tively abolished by mutation of the cysteine at position-3,
but not at position-6 (Fig. 6 A). The kinetics of membrane
association of C3S-Fyn (Fig. 6 A) were similar to v-Src
(Fig. 2 B) because a significant amount of newly synthe-
sized protein was found in the soluble fraction, shifting
slowly to the membrane fractions. Newly synthesized C6S-
Fyn (Fig. 6 A), however, exhibited membrane binding ki-
netics indistinguishable from that of wt Fyn (Fig. 2 A).
C3S-C6S-Fyn, the construct containing cysteine to serine
replacements at both positions 3 and 6 (Table I), behaved
in a manner identical to C3S-Fyn (not shown) confirming
the observation that cysteine-3 is essential for rapid mem-
brane targeting.
A parallel set of experiments was performed with poten-
tial “gain of function” mutations in Src, in which serines at
positions-3 or -6 were replaced by cysteines (1). Introduc-
tion of a cysteine residue at position-3 selectively con-
ferred rapid membrane binding to Src; radiolabeled S3C-
Src protein shifted rapidly (,5 min) to the P100 fractions,
very similar to the Fyn(14)Src construct (Fig. 6 B). How-
ever, biosynthetic S6C-Src (Fig. 6 B) displayed the same
membrane binding kinetics as v-Src (Fig. 2 B). We have
previously established that S3C-Src, but not S6C-Src, is
palmitoylated in COS-1 cells (1). We conclude that the
presence of a palmitoylated cysteine at position-3 in the
N-myristoylated Src family members is necessary and suf-
ficient for rapid membrane targeting.
Acylation and Membrane Binding of Gao-, Gas-, and 
GAP43-Fyn Chimeras
Three additional chimeric Fyn constructs were designed in
order to independently evaluate the roles of myristate,
palmitate, and the surrounding amino acid sequence in
rapid membrane binding. The first 10 amino acids of Fyn
were replaced with those of other palmitoylated proteins
(Gao, Gas, or GAP43), providing Fyn chimeras (Table I)
with specific variations on the NH2-terminal Met-Gly-Cys
sequence involved in myristoylation and palmitoylation of
Src family proteins (1, 4). The NH2-terminal sequence of
Gao(10)-Fyn contains Met-Gly-Cys and is expected to be
dually acylated with myristate and palmitate. The Gas(10)-
Fyn chimeric protein also contains the Met-Gly-Cys se-
quence, as well as an asparagine residue at position 6
(Table I), which precludes N-myristoylation (20). GAP43
(10)-Fyn does not encode an N-myristoylation site, as it
contains a leucine at position 2, but it has two palmitoyla-
tion sites in the cysteines at positions 3 and 4 (30).
COS-1 cells were transfected with the cDNAs for Gao(10)-
Fyn, Gas(10)-Fyn, and GAP43(10)-Fyn, and cells were la-
beled with either [35S]methionine, 13-[125I]iodotridecanoic
acid (IC13), an iodinated myristate analogue (36) or 16-
[125I]iodohexadecanoic acid (IC16), and an iodinated palmi-
tate analogue (36). Cells were lysed, immunoprecipitated
with anti-Fyn antibody, and analyzed by SDS-PAGE and
autoradiography. The labeling patterns for wt Fyn and the
Gao(10)-Fyn, Gas(10)-Fyn, and GAP43(10)-Fyn contructs
are depicted in Fig. 7. All constructs were expressed to
similar levels (Fig. 7, top row). In agreement with earlier
observations (1), Fyn was found to incorporate both the
labeled IC13 and IC16 analogues. Gao(10)-Fyn also incor-
porated both analogues, although the IC16 incorporation
was slightly lower (Fig. 7), likely reflecting the presence of
Figure 6. Membrane binding of newly synthesized Fyn or Src chi-
meric or mutant constructs. COS-1 cells were transfected with
chimeric constructs and mutants of Fyn (see Table I). Trans-
fected cells were radiolabeled and fractionated as described in
the legend to Fig. 1. Quantitation was performed by phosphorim-
aging, after exposure of the gels for 2–5 d.
Figure 7. Fatty acylation of Gao(10)-Fyn, Gas(10)-Fyn, and
GAP43(10)-Fyn chimeras. COS-1 cells, transfected with Fyn,
Gao(10)-Fyn, Gas(10)-Fyn, and GAP43(10)-Fyn chimeric con-
structs (see Materials and Methods and Table I) were labeled
with either [35S]methionine (top row), 13-[125I]iodotridecanoic
acid (middle row), or 16-[125I]iodohexadecanoic acid (lower row)
as described in the Materials and Methods section. Cell lysates
were immunoprecipitated with anti-fyn antibody and analyzed by
SDS-PAGE and autoradiography. Strips corresponding to the re-
gion of the gel containing p59 fyn are shown. No other radiola-
beled proteins were apparent on the gel.The Journal of Cell Biology, Volume 136, 1997 1030
only one cysteine residue in the NH2-terminal region (Ta-
ble I). Gas(10)-Fyn did not incorporate IC13 or IC16, even
though the protein was expressed at similar levels to the
other constructs. This result was surprising since full-
length Gas has been reported to be palmitoylated (8, 28,
35). For GAP43(10)-Fyn, significant incorporation of IC16
was observed, whereas only trace amounts of IC13 were
found. Incorporation of minor amounts of IC13 into
GAP43(10)-Fyn may be due to a certain degree of nonspe-
cific recognition of fatty acids by the palmitoyl acyltrans-
ferase (PAT) activity (3). Conversion of IC13 into other
fatty acids followed by incorporation into the protein
seems less likely as this was not observed for the Gas(10)-
Fyn construct. For all constructs, identical labeling pat-
terns were obtained using [3H]myristate and [3H]palmitate
instead of IC13 and IC16 (not shown).
The chimeric Fyn constructs were then tested in the bio-
synthetic membrane targeting assay (Fig. 8). Transfected
COS-1 cells were radiolabeled for 1, 2, 5, 10, 20, and 120
min at 378C, homogenized, fractionated into S100 and
P100 fractions, and analyzed by SDS-PAGE after immu-
noprecipitation as before. The Gao(10)-Fyn construct, like
wt Fyn, became rapidly enriched in the membrane frac-
tions. Nearly 65% of newly synthesized Gao(10)-Fyn was
found in the P100 fraction after labeling for 1 min, shifting
to 75% in the P100 after 5 min and 90% at steady state af-
ter 120 min (Fig. 8). The Gas(10)-Fyn construct, which is
neither myristoylated nor palmitoylated (Fig. 7), behaved
as the G2A-Fyn construct (Fig. 6 A), remaining 60–70%
soluble over the time course of the experiment (Fig. 8). In-
terestingly, GAP43(10)-Fyn displayed a slow membrane
targeting phenotype, very similar to v-Src. After 1, 2, and 5
min the majority was still in the soluble fraction, shifting to
60% membrane bound after 20 min. The major difference
between GAP43(10)-Fyn and v-Src was the higher amount
of GAP43(10)-Fyn in the P100 fraction at steady state (cf.
Figs. 2 B and Fig. 8). Thus, although the GAP43 sequence
directed incorporation of palmitate and membrane bind-
ing at steady state, it was not sufficient to direct rapid bio-
synthetic membrane anchoring. These observations sub-
stantiate the conclusion that rapid membrane targeting of
newly synthesized Fyn is exclusively conferred by the combi-
nation of NH2-terminal myristoylation plus palmitoylation.
Newly Synthesized Fyn Colocalizes
with the Plasma Membrane
We next assessed the intracellular localization of newly
synthesized Fyn by analysis of homogenates on linear den-
sity gradients and comparison to marker enzyme activities
for the ER, Golgi complex, and the plasma membrane
(Fig. 9). For these experiments, NIH-3T3 fibroblasts stably
expressing Fyn were used, in combination with iodixanol
gradients. The stable 3T3 cells were used because fraction-
ation of subcellular organelles from transiently transfected
COS-1 cells was very difficult, likely due to the presence of
DEAE-dextrans in the transfection mix. Iodixanol (Op-
tiPrepTM) gradients allowed for a significant separation of
plasma membrane marker activity from ER and Golgi ac-
tivities (Fig. 9), which was not accomplished using sucrose
density gradients (not shown). Confluent monolayers of
NIH-3T3 cells expressing Fyn were radiolabeled with
[35S]methionine for 5 min (Fig. 5), followed by homogeni-
zation in an isotonic buffer, preparation of a P100 fraction,
and centrifugation through continuous Iodixanol (25–2.5%
wt/vol OptiPrepTM) gradients. Gradients were fraction-
ated from the bottom (left) to the top (right) and samples
were taken for marker enzyme analysis. a-Glucosidase II
was measured as a marker for endoplasmic reticulum (top
panel), a-mannosidase II as a Golgi marker (middle panel)
and alkaline phosphatase as a plasma membrane marker
(bottom panel). The distribution of newly synthesized Fyn
protein was assayed by immunoprecipitation of each gra-
dient fraction with anti-Fyn antibody, followed by SDS-
PAGE and phosphorimager analysis. The data depicted in
Fig. 9 show that newly synthesized Fyn was recovered
from light membrane fractions at low Iodixanol densities,
exactly overlapping with alkaline phosphatase activity, a
marker for the plasma membrane. Little colocalization
was observed with ER or Golgi (Fig. 9) or denser or-
ganelles such as mitochondria and lysosomes (not shown).
Identical results were obtained after adjusting P100 frac-
tions to 25% wt/vol Iodixanol and applying them to the
bottom of the density gradients before centrifugation (not
shown), indicating that the light fraction in Fig. 8 is a genu-
ine membrane fraction with a low buoyant density. In
pulse-chase experiments, where Fyn was labeled for 5 min
and chased for 2 h, the radiolabeled protein did not shift to
a different location in density gradients (not shown). These
results imply that newly synthesized Fyn becomes rapidly
targeted to a light-density, plasma membrane-enriched
fraction of the cell within minutes after its release from the
ribosome.
Binding of Newly Synthesized Fyn to Non-ionic 
Detergent Resistant Fractions Occurs with a Slower 
Time Course
Previous studies, using assays with non-ionic detergents,
have suggested that the Src family members Fyn and Lck
interact with subspecialized regions of the plasma mem-
brane, enriched in the caveolar marker protein, caveolin
(47). Based on this and other work (42, 43, 48), it was hy-
pothesized that dual acylation with myristate and palmi-
tate provides a targeting signal for localization to caveolae
and/or other detergent resistant structures (29). It is not
known whether acquisition of detergent insolubility pre-
Figure 8. Membrane binding of newly synthesized Gao(10)-Fyn,
Gas(10)-Fyn, and GAP43(10)-Fyn chimeras. COS-1 cells were
transfected with chimeric constructs (see Table I) and radiola-
beled, homogenized, and fractionated as described in the legend
under Fig. 1. Quantitation was performed by phosphorimaging,
after exposure to the gels for 2–5 d. Numbers are the mean of two
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cedes or is dependent on membrane binding. Therefore, to
study the intracellular fate of biosynthetic Fyn in more de-
tail, we directly compared the kinetics of membrane bind-
ing with resistance to 1% Triton X-100 extraction in trans-
fected COS-1 cells. The characteristic rapid membrane
binding of Fyn is depicted in Fig. 10, with Fyn becoming
entirely membrane-bound within 4 min after the start of
biosynthesis. However, at these same early time points (1,
2, and 4 min) the majority (70%) of radiolabeled Fyn was
detected in detergent soluble fractions (Fig. 10). The
amount of newly synthesized Fyn that was detected in the
Triton X-100 resistant fraction at the early timepoints
(30%) was similar to that remaining after extraction with
1% Triton X-100 solutions supplemented with deoxycho-
late and NP-40 (not shown). In addition, this amount is
similar to that of the soluble marker protein b-Gal found
in the Triton X-100 resistant fraction at steady state, as
measured by Western blotting. This indicates that there is
approximately a 30% background in the detergent resis-
tant fraction in these experiments. By 6, 8, and 10 min, Fyn
became more detergent-resistant, reaching a steady-state
level of 55% detergent insolubility after 20 min (Fig. 10).
The observed lag-time of 10–20 min between membrane
binding of newly synthesized Fyn and enrichment in the
detergent resistant fraction strongly suggests that mem-
brane binding of Fyn occurs first, followed by relocaliza-
tion into a detergent-resistant fraction of the cell.
Discussion
Participation of the Src family of nonreceptor tyrosine ki-
nases in signal transduction and cellular transformation re-
quires their binding to cellular membranes. The mecha-
nisms involved in the transport of Src family proteins from
their site of synthesis to membranes remain unknown. All
Figure 9. Density gradient analysis of newly synthesized Fyn.
Stably transfected NIH-3T3 cells, expressing wt Fyn were radio-
labeled for 5 min at 378C with 500 mCi/ml [35S]methionine as de-
scribed under Materials and Methods. For each gradient cells
from six semi-confluent 100-mm dishes were homogenized in iso-
tonic buffer. After removal of intact cells and nuclei, a P100 frac-
tion was prepared and applied to continuous Iodixanol (25%–
2.5% wt/vol OptiPrepTM) gradients. Gradients were fractionated
from bottom to top (left to right in the figure) and samples were
taken for marker enzyme analysis. a-Glucosidase II was mea-
sured as a marker for endoplasmic reticulum (top panel), a-man-
nosidase II as a Golgi marker (middle panel), and alkaline phos-
phatase as a plasma membrane marker (bottom panel). The
distribution of newly synthesized Fyn protein was assayed by sub-
jecting the remainder of each gradient fraction to immunoprecip-
itation, followed by SDS-PAGE. The intensity of labeled Fyn in
each fraction was measured by phosphorimaging, after exposure
for 4–6 wk.
Figure 10. Non-ionic detergent extraction of newly synthesized
Fyn. COS-1 cells were transfected with cDNA encoding wild-type
Fyn as before. Transfected cells on 60-mm plastic dishes were ra-
diolabeled with 100 mCi/ml [35S]methionine for the indicated
times at 378C, and incubated for 5 min at 48C with Csk buffer (see
Materials and Methods) containing 1% Triton X-100, followed
by a wash with Csk buffer. The detergent solutions containing de-
tergent soluble material were pooled and supplemented with lysis
buffer. The remaining detergent resistant fractions were scraped
from the plates in lysis buffer. Both fractions were clarified and
analyzed by immunoprecipitation and SDS-PAGE. In a parallel
experiment, cells were fractionated into P100 and S100 fractions
as described in the legends to Figs. 1, 2, and 5. Membrane binding
and association of newly synthesized Fyn into detergent insoluble
complexes was measured by phosphorimaging after exposure for
2–4 d. The graphed values, obtained from four experiments, rep-
resent the percentage of total signal recovered in P100 fractions
(closed circles) or the Triton X-100 resistant fraction (closed tri-
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Src family members contain the fatty acid myristate, which
is essential, but not sufficient for membrane binding and
cell signaling. We aimed to determine whether the re-
cently described dynamic modification of certain Src fam-
ily members with palmitate is involved in intracellular tar-
geting, using Fyn as a model. Here we demonstrate that
the presence of the NH2-terminal sequence Met-Gly-Cys,
the consensus sequence for dual myristoylation and palmi-
toylation of Src family members, directs rapid membrane
targeting of newly synthesized Fyn. The rapidity of mem-
brane binding for Fyn is striking (within 1–4 min after bio-
synthesis) and stands in distinct contrast to the slower ki-
netics of membrane binding of nonpalmitoylated Src.
Dual Fatty Acylation Is Required for Rapid
Membrane Targeting
Five lines of evidence support the conclusion that the com-
bination of myristate plus palmitate at the NH2 terminus
of Src family proteins directs rapid membrane binding of
newly synthesized polypeptides. First, mutation of cys-
teine-3, a major palmitoylation site in Fyn (1), slows the
kinetics as well as the extent of membrane binding of
newly synthesized protein (Fig. 6 A). Second, introduction
of a single cysteine at position 3 in Src converts the mem-
brane binding of Src from “slow” to rapid (Fig. 6 B). The
S3C mutation has previously been shown by our labora-
tory to induce palmitoylation of Src (1). Third, Gao-Fyn, a
chimeric protein which is both myristoylated and palmi-
toylated but contains a different amino acid sequence
from position 4-10, displayed rapid binding kinetics identi-
cal to wild-type Fyn (Fig. 8). Fourth, although the Met-
Gly-Cys sequence is present at the NH2 terminus of Gas-
Fyn (Table I, Fig. 7), only low levels of membrane binding
are observed, presumably due to the lack of palmitoyla-
tion. Thus, palmitoylation of cysteine-3, rather than the
mere presence of cysteine-3, is required for rapid mem-
brane anchoring. Fifth, the GAP43-Fyn chimera, which is
palmitoylated but not myristoylated (Fig. 7), exhibits slow
membrane binding (Fig. 8), even though .85% of the
GAP43-Fyn protein is membrane bound at steady state
(Fig. 8). It is noteworthy that the NH2-terminal sequence
of GAP43-Fyn includes three basic amino acid residues,
two arginines and a lysine (Table I). Therefore, the two-
signal mode for membrane binding of GAP43-Fyn may
consist of palmitate plus basic amino acids, analogous to
the myristate plus basic amino acid motif of Src.
The data we have presented strongly suggests that Fyn is
already dually acylated within 5 min after biosynthesis.
N-myristoylation is known to be a cotranslational modifi-
cation (54), which occurs as the NH2 terminus of the na-
scent chain is exposed from the ribosome (10). Protein
palmitoylation has been classified as a posttranslational
modification, based on the relative resistance of radiolabel
incorporation to treatment with protein synthesis inhibi-
tors such as cycloheximide (34). Our data, however, imply
that palmitoylation must be occurring relatively soon after
protein synthesis has been completed. It is not possible to
directly address this issue by pulse-chase analysis with ra-
diolabeled palmitate, since this would not only radiolabel
newly synthesized Fyn, but also the pool of existing Fyn
undergoing cycles of acylation/deacylation. Instead, we an-
alyzed the effects of protein synthesis inhibitors on palmi-
toylation of Fyn. Transfected COS-1 cells were pre-treated
for 1 h at 378C with 50 mg/ml cycloheximide and then radio-
labeled for 2 h at 378C with either [35S]methionine, IC13, or
IC16 in the presence of cycloheximide. Incorporation of
[35S]methionine and IC13 was nearly completely inhibited
(.95%), confirming that N-myristoylation is tightly de-
pendent on ongoing protein synthesis. However, levels of
IC16 incorporation were also reduced by 65–70%, com-
pared to untreated controls (data not shown). These results
confirm that some level of palmitoylation of Fyn can occur
in the absence of protein synthesis, but importantly, they
also imply that a significant fraction of the radiolabeled
palmitate is actually incorporated into newly synthesized
Fyn polypeptide.
Our results suggest that palmitoylation is a critical pro-
cess in determining the intracellular destination of newly
synthesized Fyn. Recently, uncatalyzed, acyl-CoA–depen-
dent auto acylation of cysteine-containing lipopeptides or
G protein a subunits has been shown to occur in vitro (11,
38). Three observations argue against an uncatalyzed trans-
acylation mechanism to drive rapid membrane binding of
Fyn after biosynthesis. First, the exclusive requirement for
a cysteine at position-3 but not at position-6 (Fig. 6), and
the essential combination with N-myristoylation (Fig. 8)
imply that a specific protein-mediated mechanism is in-
volved. Second, the fastest time scale observed for uncata-
lyzed transacylation in vitro was on the order of tens of
minutes, still an order of magnitude slower than the in vivo
membrane binding of Fyn. Third, nonenzymatic acylation
of Fyn is expected to occur preferentially at intracellular
sites with high local concentrations of fatty acids and acyl-
CoA-precursors. In intact cells, such a location accessible
to soluble Fyn consists of the cytoplasmic membrane as-
pect of the ER, which is involved in the biosynthesis of
phospholipids and ceramides. Newly synthesized Fyn,
however, was specifically localized to plasma membrane
enriched fraction in density gradients, was entirely absent
from the ER fractions at higher densities, and only slightly
overlapped with the Golgi complex (Fig. 9). Dunphy et al.
(1996) have recently documented the presence of a spe-
cific PAT activity in the plasma membrane (12). These ob-
servations, therefore, suggest that a protein palmitoyl
transferase (PAT) could be the critical component in de-
termining the intracellular destination of newly synthe-
sized Fyn as opposed to random diffusion and trapping of
soluble Fyn by non-enzymatic acylation reactions.
Intracellular Trafficking of Fyn
Few studies have examined the biosynthetic trafficking
pathways of Src family members. In early work, v-Src was
reported to be synthesized on free ribosomes in the cyto-
sol (25). Pulse-chase analysis of Rous sarcoma virus-trans-
formed NRK cells revealed that newly synthesized v-Src
shifted from the soluble to the membrane fraction in 5–10
min (26). No study to date has investigated the intracellu-
lar trafficking pattern of the dually acylated Src family
members (e.g., Fyn, Lck). The data we have presented in-
dicate that Fyn is synthesized on soluble polysomes and is
released into the cytosol as a soluble protein. Although the
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fractions were generally low, its cytoplasmic origin was
also upheld by the larger cytosolic pools of labeled G2A-
Fyn and C3S-Fyn mutant protein (Fig. 6 a). Rapid associa-
tion with plasma membranes (or a membrane fraction of
similar density) then occurs (Fig. 9), followed by a slower
partitioning of the protein into a detergent-resistant ma-
trix (Fig. 10). These results constitute the first demonstra-
tion of a unique trafficking pathway for a dually fatty acy-
lated protein, which is characterized by its rapid kinetics, and
underscore the importance of fatty acid acylation not only
for membrane binding, but also for protein trafficking.
The molecular mechanism behind the novel trafficking
pathway that is followed by Fyn between the cytosol and
the plasma membrane remains unknown. However, the
observation that a single serine to cysteine replacement at
position-3 is sufficient to generate rapid membrane target-
ing of Src (Fig. 6 b), suggests that the transport mecha-
nisms used by Fyn and Src are very closely related. Previ-
ous studies on Src have shown that newly synthesized
polypeptide complexes with two proteins, pp50 and pp90,
in the cytosol (5, 33). It has been proposed that the pp50/pp90
complex may deliver newly synthesized v-Src and other
proteins to the plasma membrane (7). However, other stud-
ies imply that the pp50-pp90 complex functions to stabilize
tyrosine kinase activity of the soluble form of v-Src (18,
55). We have also observed proteins of z50 and z90 kD
that co-immunoprecipitate with newly synthesized Fyn in
soluble fractions (not shown). In the absence of specific in-
hibitors to trap or arrest Fyn in the cytosolic fraction how-
ever (see below), the detectable pools of newly synthe-
sized Fyn in soluble fractions were low. As a consequence,
the levels of coprecipitating proteins were also low and in-
consistent and the significance of these observations there-
fore remain unclear.
In an attempt to classify the mechanism involved in
rapid membrane trafficking of dually acylated proteins, a
variety of drugs was used in the membrane binding assay.
Inhibitors of vesicular trafficking of newly synthesized
transmembrane and secretory proteins from the ER to the
plasma membrane (Brefeldin A, monensin, etc.) had no
effect on either the kinetics or extent of membrane bind-
ing of newly synthesized Fyn (data not shown). In addi-
tion, the microtubule-disrupting agents nocodazole and
colchicine and the actin stress-fiber depolymerizing drug
cytochalasin D did not interfere with rapid membrane
binding of Fyn (data not shown). Finally, the general ty-
rosine-kinase inhibitor genistein and the PI-3 kinase inhib-
itor wortmannin were also ineffective. The absence of any
inhibitory effect of these drugs accentuates the unique na-
ture of this novel membrane trafficking pathway.
Plasma Membrane Localization
of Newly Synthesized Fyn
Varying observations have been reported with respect to
the steady-state intracellular distribution of Fyn. In human
T-lymphocytes, Fyn was mainly associated with centroso-
mal structures (27) or exclusively in association with the T
cell receptor complex at the plasma membrane (15). Im-
munofluorescence studies in NIH 3T3 cells have localized
Fyn to both the plasma membrane and intracellular, peri-
nuclear membranes. We have seen a similar distribution of
Fyn overexpressed in COS-1 cells (data not shown). Analy-
sis of newly synthesized Fyn in NIH 3T3 cells on density
gradients revealed that Fyn colocalized with plasma mem-
brane marker proteins (Fig. 9). It is known that endosomal
membranes can have densities similar to that of the
plasma membrane and we can at present not rule out that
newly synthesized Fyn rapidly associates with an endoso-
mal fraction first, serving as a shuttle to the plasma mem-
brane. Alternatively, the “slow” kinetics of membrane
binding exhibited by Src could reflect routing to an intra-
cellular membrane compartment, and indeed, a significant
portion of c-Src is found in the endosomal fraction in fi-
broblastic cells (21). We are currently applying more de-
tailed fractionation assays in order to resolve these issues.
A number of studies have documented that the myr-
Gly-Cys motif serves as a signal for partitioning of dually
acylated Src family members to the non-ionic detergent
resistant matrix, often referred to as cytoskeleton (17),
GEM, DIG, or caveolae (29, 42, 43). These structures are
considered to be subspecialized regions of the plasma
membrane and/or are found in close proximity to the
plasma membrane. We therefore examined the kinetics of
association of newly synthesized Fyn with the Triton-resis-
tant fraction and compared them with binding of Fyn to
membranes. We observed that membrane binding of
newly synthesized Fyn precedes acquisition of detergent
resistance by 10–20 min (Fig. 10). From the distinct kinet-
ics it appears clear that dual acylation is a prerequisite, but
not a direct targeting signal to the detergent resistant
plasma membrane specializations, that may represent cy-
toskeleton or caveolae. Which cellular event causes the lag
between membrane binding and acquisition of detergent
insolubility of Fyn remains an open question. It seems un-
likely that it reflects lateral diffusion of Fyn, from the site
of insertion in the plasma membrane to the detergent-
resistant plasma membrane specialization, as lateral diffu-
sion of membrane-bound proteins generally occurs on the
order of seconds (13). It is possible that the observed lag-
time reflects rapid association of newly synthesized Fyn
with an endosomal membrane fraction, as discussed above,
followed by translocation to the plasma membrane via a
vesicular mechanism and association with the detergent
resistant matrix.
Intracellular Targeting of Fyn: A Kinetic “Bilayer 
Trapping” Model
Our data show a strict correlation between the myr-Gly-
Cys motif, dual fatty acylation, and rapid plasma mem-
brane targeting of Fyn. As discussed above, it is still not
possible to determine precisely whether palmitoylation
precedes membrane binding of Fyn or vice versa. Several
lines of evidence suggest that palmitoylation is occurring
at the plasma membrane. The palmitoyl acyltransferase
activities that palmitoylate Fyn (3) and Ga subunits (12)
are membrane bound, enriched in plasma membrane frac-
tions (12), and substrates which are membrane bound are
preferentially palmitoylated. For example, we have found
that anchoring of a nonmyristoylated Fyn (G2A-Fyn) to
the plasma membrane via a COOH-terminal K-Ras4B tail
allows for palmitoylation of cysteine-3 of Fyn (van’t Hof,
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observations). A similar result was obtained for palmitoy-
lation of Gai subunits in vivo (9). Moreover, in vitro palmi-
toylation assays require the presence of detergent micelles
for efficient palmitoylation (4, 12), implying that the colo-
calization of enzyme and substrate in a lipid bilayer en-
hances protein palmitoylation. Finally, Silvius and coworkers
have recently shown that lipid-modified, cysteinyl-containing
peptides, containing myr-Gly-Cys motifs as found at the
NH2 terminus of Fyn, are preferentially palmitoylated and
localized at the plasma membrane (45).
Taken together, the available data presented in this
manuscript and previous work suggests the following
model. Fyn is synthesized on cytosolic polysomes as a solu-
ble protein and is rapidly and specifically trafficked/shut-
tled to the plasma membrane, where it is palmitoylated by
a plasma membrane bound palmitoyl transferase (12, 45).
The dually acylated protein now becomes tightly bound to
the plasma membrane bilayer where it remains essentially
“trapped” due to the strong hydrophobicity of the dual
fatty acid anchor. Our data thus provide experimental sup-
port for the kinetic bilayer trapping mechanism recently
proposed by Shahinian and Silvius (46). Future studies will
be directed towards understanding the functional signifi-
cance of rapid plasma membrane targeting of newly syn-
thesized Fyn.
We are grateful to Drs. Michele Fuortes and Michael Shiloh in the labora-
tory of Dr. Carl Nathan at Cornell University Medical College, for expert
assistance in using the CytoFluor Fluorescent platereader, and to Dr.
Martin Wiedmann (Sloan-Kettering Institute for Cancer Research, New
York) for advice on the flotation assay for membrane-bound polyribo-
somes. We thank Vera Bonilha for assistance with preparing the figures,
Raya Louft-Nisenbaum for technical assistance, Melissa Ray for secre-
tarial support and Amy Wolven for critically reading the manuscript.
This work was supported by a grant from the American Cancer Society
to M.D. Resh (VM4H). M.D. Resh is an Established Scientist of the
American Heart Association. W. van’t Hof is a Miriam and Benedict Wolf
Cancer Research fellow. 
Received for publication 23 December 1996.
References
1. Alland, L., S.M. Peseckis, R.E. Atherton, L. Berthiaume, and M.D. Resh.
1994. Dual myristylation and palmitylation of Src family member p59fyn
affects subcellular localization. J. Biol. Chem. 269:16701–16705.
2. Appleby, M.W., J.A. Gross, M.P. Cooke, S.D. Levin, X. Qian, and R.M.
Perlmutter. 1992. Defective T cell receptor signaling in mice lacking the
thymic isoform of p59fyn. Cell. 70:751–753.
3. Berthiaume, L., and M.D. Resh. 1995. Biochemical characterization of a
palmitoyl acyltransferase activity that palmitoylates myristylated pro-
teins.  J. Biol. Chem. 270:22399–22405.
4. Berthiaume, L., S.M. Peseckis, and M.D. Resh. 1995. Synthesis and use of
Iodo-fatty acid analogs. Methods Enzymol. 250:454–466.
5. Brugge, J.S. 1986. Interaction of the Rous sarcoma virus protein pp60src
with the cellular proteins pp50 and pp90. Curr. Topics Microbiol. Immu-
nol. 123:1–22.
6. Casey, P.J. 1995. Protein lipidation in cell signaling. Science (Wash. DC).
268:221–225.
7. Courtneidge, S.A., and J.M. Bishop. 1982. Transit of pp60v-src to the plasma
membrane. Proc. Natl. Acad. Sci. USA. 79:7117–7121.
8. Degtyarev, M.Y., A.M. Spiegel, and T.L. Jones. 1993. The G protein alpha
s subunit incorporates [3H]palmitic acid and mutation of cysteine-3 pre-
vents this modification. Biochemistry. 32:8057–8061.
9. Degtyarev, M.Y., A.M. Spiegel, and T.L.Z. Jones. 1994. Palmitoylation of a
G protein ai subunit requires membrane localization not myristoylation.
J. Biol. Chem. 269:30989–30903.
10. Deichaite, I., L.P. Casson, H.-P. Ling, and M.D. Resh. 1988. In vitro syn-
thesis of pp60v-src: myristylation in a cell-free system. Mol. Cell. Biol. 8:
4295–4301.
11. Duncan, J.A., and A.G. Gilman. 1996. Autoacylation of G protein a sub-
units. J. Biol. Chem. 271:23594–23600.
12. Dunphy, J.T., W.K. Greentree, C.L. Manahan, and M.E. Linder. 1996.
G-protein palmitoyltransferase activity is enriched in plasma membranes.
J. Biol. Chem. 271:7154–7159.
13. Edidin, M. 1991. Translational diffusion of membrane proteins. In The
Structure of Biological Membranes. P. Yeagle, editor. CRC Press Inc.,
Boca Raton, FL. 539–572.
14. Franzen, P., P. ten Dijke, H. Ichijo, H. Yamashita, P. Schulz, C.-H. Heldin,
and K. Miyazono. 1993. Cloning of a TGFb type I receptor that forms a
heteromeric complex with the TGFb type II receptor. Cell. 75:681–692.
15. Gassmann, M., M. Guttinger, K.E. Amrein, and P. Burn. 1992. Protein ty-
rosine kinase p59fyn is associated with the T cell receptor-CD3 complex in
functional human lymphocytes. Eur. J. Immunol. 22:283–286.
16. Glomset, J.A., and C.C. Farnsworth. 1994. Role of protein modification re-
actions in programming interactions between Ras-related GTP-ases and
cell membranes. Annu. Rev. Cell Biol. 10:181–205.
17. Hamaguchi, M., and H. Hanafusa. 1987. Association of p60src with Triton
X-100-resistant cellular structure correlates with morphological transfor-
mation. Proc. Natl. Acad. Sci. USA. 84:2313–2316.
18. Hartson, S.D., and R.L. Matts. 1994. Association of Hsp90 with cellular
Src-family kinases in a cell-free system correlates with altered kinase
structure and function. Biochemistry. 33:8912–8920.
19. James, G., and E.N. Olson. 1990. Fatty acylated proteins as components of
intracellular signaling pathways. Biochemistry. 29:2623–2634.
20. Johnson, D.R., R.S. Bhatnagar, L.J. Knoll, and J.I. Gordon. 1994. Genetic
and biochemical studies of protein N-myristoylation. Annu. Rev. Bio-
chem. 63:869–914.
21. Kaplan, K.B., J.R. Swedlow, H.E. Varmus, and D.O. Morgan. 1992. Asso-
ciation of p60c-src with endosomal membranes in mammalian fibroblasts.
J. Cell Biol. 118:321–333.
22. Kosik, K.S., L.D. Orecchio, G.A. Bruns, L.I. Benowitz, G.P. MacDonald,
D.R. Cox, and R.L. Neve. 1988. Human GAP-43: its deduced amino acid
sequence and chromosomal localization in mouse and human. Neuron. 1:
127–132.
23. Kozasa, T., H. Itoh, T. Tsukamoto, and Y. Kaziro. 1988. Isolation and char-
acterization of the human Gs alpha gene. Proc. Natl. Acad. Sci. USA. 85:
2081–2085.
24. Lauring, B., H. Sakai, G. Kreibich, and M. Wiedmann. 1995. Nascent
polypeptide-associated complex protein prevents mistargeting of nascent
chains to the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA. 92:
5411–5414.
25. Lee, J.S., H.E. Varmus, and J.M. Bishop. 1979. Virus-specific messenger
RNAs in permissive cells infected by avian sarcoma virus. J. Biol. Chem.
254:8015–8022.
26. Levinson, A.D., S.A. Courtneidge, and J.M. Bishop. 1981. Structural and
functional domains of the Rous sarcoma virus transforming protein
(pp60src).  Proc. Natl. Acad. Sci. USA. 78:1624–1628.
27. Ley, S.C., M. Marsh, C.R. Bebbington, K. Proudfoot, and P. Jordan. 1994.
Distinct intracellular localization of Lck and Fyn protein tyrosine kinases
in human T-lymphocytes. J. Cell Biol. 125:639–649.
28. Linder, M.E., P. Middleton, J.R. Hepler, R. Taussig, A.G. Gilman, and
S.M. Mumby. 1993. Lipid modifications of G proteins: alpha subunits are
palmitoylated. Proc. Natl. Acad. Sci. USA. 90:3675–3679.
29. Lisanti, M.P., P.E. Scherer, Z.L. Tang, and M. Sargiacomo. 1994. Caveolae,
caveolin and caveolin-rich membrane domains: a signalling hypothesis.
Trends Cell Biol. 4:231–235.
30. Liu, Y., D.A. Fisher, and D.R. Storm. 1993. Analysis of the palmitoylation
and membrane targeting domain of neuromodulin (GAP43) by site-spe-
cific mutagenesis. Biochemistry. 32:10714–10719.
31. Lowy, D.R., and B.M. Willumsen. 1993. Function and regulation of Ras.
Annu. Rev. Biochem. 62:851–891.
32. McLaughlin, S., and A. Aderem. 1995. The myristoyl-electrostatic switch: a
modulator of reversible protein-membrane interactions. TIBS. 20:272–
276.
33. Oppermann, H., A.D. Levinson, L. Levintow, H.E. Varmus, J.M. Bishop,
and S. Kawai. 1981. Two cellular proteins that immunoprecipitate with
the transforming protein of Rous sarcoma virus. Virology. 113:736–751.
34. Paige, L.A., M.J.S. Nadler, M.L. Harrison, J.M. Cassady, and R.L.
Geahlen. 1993. Reversible palmitoylation of the protein-tyrosine kinase
p56lck. J. Biol. Chem. 268:8669–8674.
35. Parenti, M., M.A. Vigano, C.M. Newman, G. Milligan, and A.I. Magee.
1993. A novel N-terminal motif for palmitoylation of G-protein alpha
subunits. Biochem. J. 291:349–353.
36. Peseckis, S.M., I. Deichaite, and M.D. Resh. 1993. Iodinated fatty acids as
probes for myristate processing and function. Incorporation into pp60v-src.
J. Biol. Chem. 268:5107–5114.
37. Picard, D., and K. Yamamoto. 1987. Two signals mediate hormone-depen-
dent nuclear localization of the glucocorticoid receptor. EMBO (Eur.
Mol. Biol. Organ.) J. 6:3333–3340.
38. Quesnel, S., and J. R. Silvius. 1994. Cysteine-containing peptide sequences
exhibit facile uncatalyzed transacylation and acyl-CoA-dependent acyla-
tion at the lipid bilayer interface. Biochemistry. 33:13340–13348.
39. Resh, M.D. 1993. Interaction of tyrosine kinase oncoproteins with cellular
membranes. Biochim. Biophys. Acta. 1155:307–322.
40. Resh, M.D. 1994. Myristylation and palmitylation of Src family members:
the fats of the matter. Cell. 76:422–413.van ’t Hof and Resh Biosynthesis and Plasma Membrane Targeting of Fyn 1035
41. Resh, M.D. 1996. Regulation of cellular signaling by fatty acid acylation
and prenylation of signal transduction proteins. Cell Signaling. 8:403–412.
42. Robbins, S.M., N.A. Quintrell, and J.M. Bishop. 1995. Myristoylation and
differential palmitoylation of the HCK protein-tyrosine kinases govern
their attachment to membranes and association with caveolae. Mol. Cell.
Biol. 15:3507–3515.
43. Rodgers, W., B. Crise, and J.K. Rose. 1994. Signals determining protein ty-
rosine kinase and glycosyl-phosphatidylinositol-anchored protein target-
ing to a glycolipid-enriched membrane fraction. Mol. Cell. Biol. 14:5384–
5391.
44. Rothman, J.E., and L. Orci. 1992. Molecular dissection of the secretory
pathway. Nature (Lond.). 355:409–415.
45. Schroeder, H., R. Leventis, S. Shahinian, P.A. Walton, and J.R. Silvius.
1996. Lipid-modified, cysteinyl-containing peptides of diverse structures
are efficiently S-acylated at the plasma membrane of mammalian cells. J.
Cell Biol. 134:647–660.
46. Shahinian, S., and J. R. Silvius. 1995. Doubly-lipid-modified protein se-
quence motifs exhibit long-lived anchorage to lipid bilayer membranes.
Biochemistry. 34:3813–3822.
47. Shenoy-Scaria, A.M., D.J. Dietzen, J. Kwong, D.C. Link, and D.M. Lublin.
1994. Cysteine 3 of Src family protein tyrosine kinases determines palmi-
toylation and localization in caveolae. J. Cell Biol. 126:353–363.
48. Shenoy-Scaria, A.M., L.K.T. Gauen, J. Kwong, A.S. Shaw, and D.M. Lub-
lin. 1993. Palmitylation of an amino-terminal cysteine motif of protein ty-
rosine kinases p56lck and p59fyn mediates interaction with glycosyl-phos-
phatidylinositol-anchored proteins. Mol. Cell. Biol. 13:6385–6392.
49. Sigal, C.T., W. Zhou, C.A. Buser, S. McLaughlin, and M.D. Resh. 1994.
Amino-terminal basic residues of Src mediate membrane binding
through electrostatic interaction with acidic phospholipids. Proc. Natl.
Acad. Sci. USA. 91:12253–12257.
50. Silverman, L., and M.D. Resh. 1992. Lysine residues form an integral com-
ponent of a novel NH2-terminal membrane targeting motif for myristy-
lated pp60v-src. J. Cell Biol. 119:415–422.
51. Towler, D.A., and J.I. Gordon. 1988. The biology and enzymology of eu-
karyotic protein acylation. Annu. Rev. Biochem. 57:69–99.
52. Walter, P., and A.E. Johnson. 1994. Signal sequence recognition and pro-
tein targeting to the ER membrane. Annu. Rev. Cell Biol. 10:87–119.
53. Weis-Garcia, F., and J. Massagué. 1996. Complementation between kinase-
defective and activation-defective TGF-b receptors reveals a novel form
of receptor cooperativity essential for signaling. EMBO (Eur. Mol. Biol.
Organ.) J. 15:276–289.
54. Wilcox, C., J.-S. Hu, and E.N. Olson. 1987. Acylation of proteins with
myristic acid occurs cotranslationally. Science (Wash. DC). 238:1275–
1278.
55. Xu, Y., and S. Lindquist. 1993. Heat-shock protein hsp90 governs the activ-
ity of pp60v-src kinase. Proc. Natl. Acad. Sci. USA. 90:7074–7078.
56. Zhang, F.L., and P.J. Casey. 1996. Protein prenylation: molecular mecha-
nisms and functional consequences. Annu. Rev. Biochem. 65:241–269.
57. Zhou, W., L.J. Parent, J.W. Wills, and M.D. Resh. 1994. Identification of a
membrane binding domain within the amino terminal region of human
immunodeficiency virus-1 Gag protein which interacts with acidic phos-
pholipids. J. Virol. 68:2556–2569.